Dr. Hamza Hassan, MD

Dr. Hassan practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Hassan's NPI, 1700300837, was assigned on July 31, 2017. Dr. Hassan graduated from Rawalpindi Medical College in 2014. Dr. Hassan holds New York license 322605.

Dr. Hassan's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Hassan's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Hassan is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hassan practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Hassan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Hassan is licensed in New York.

CMS data shows 276 Medicare services from Dr. Hassan across 4 procedure codes in 2024, for 86 Medicare patients. Medicare paid $21,386 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Dr. Hassan in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hassan's median patient age at 71, with 48% women.

In 2024, Dr. Hassan wrote 118 Medicare Part D claims for 29 patients. 98% of them were for generic drugs. CMS names the drug for 87 of them, across 4 drugs with 11 or more claims each, at $2,890 in total drug cost. In 2020, CMS named 66 claims across 4 drugs.

Dr. Hassan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Hassan, published from 2019 to 2025. 2025 was the busiest year, with 5. The most frequent topics are Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma and Hematopoietic Stem Cell Transplantation. Dr. Hassan has published most often in Blood Adv. Dr. Hassan's most frequent co-authors are Vaishali Sanchorawala, MD, Faiz Anwer, MD and Camille V. Edwards, MBBS.

CMS Open Payments shows 3 general payments to Dr. Hassan from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $48.

Dr. Hassan graduated from Rawalpindi Medical College in 2014.